MCID: RTN020
MIFTS: 47

Retinal Vascular Disease

Categories: Cardiovascular diseases, Eye diseases

Aliases & Classifications for Retinal Vascular Disease

MalaCards integrated aliases for Retinal Vascular Disease:

Name: Retinal Vascular Disease 12 14
Retinal Vascular 52 69
Retina Circulation Disorder 12
Retinal Vascular Disorder 69

Classifications:



External Ids:

Disease Ontology 12 DOID:2462
NCIt 47 C35170
SNOMED-CT 64 57534004
UMLS 69 C0154833

Summaries for Retinal Vascular Disease

MalaCards based summary : Retinal Vascular Disease, also known as retinal vascular, is related to retinal vascular occlusion and congenital toxoplasmosis, and has symptoms including chest pain An important gene associated with Retinal Vascular Disease is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are mTOR signaling pathway (KEGG) and Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Bevacizumab and Ranibizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Retinal Vascular Disease

Diseases related to Retinal Vascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 82)
id Related Disease Score Top Affiliating Genes
1 retinal vascular occlusion 12.3
2 congenital toxoplasmosis 10.7 AKR1B1 SERPINF1 VEGFA
3 angular blepharoconjunctivitis 10.7 MTHFR SERPINF1 VEGFA
4 cryptosporidiosis 10.7 MTHFR PLG VEGFA
5 exudative vitreoretinopathy 10.7
6 iliac vein thrombophlebitis 10.7 KDR PLG VEGFA
7 benign familial neonatal epilepsy 10.7 KDR SERPINF1 VEGFA
8 sacrococcygeal teratoma 10.7 MTHFR SERPINF1 VEGFA
9 ovarian insufficiency, familial 10.6 MTHFR PLG VEGFA
10 hypertonia 10.6 MTHFR VEGFA
11 adult brain ependymoma 10.6 FZD4 NDP TSPAN12
12 purulent endophthalmitis 10.6 CTGF PLG VEGFA
13 placental choriocarcinoma 10.6 KDR PLG VEGFA
14 hyperaldosteronism 10.6 ICAM1 SERPINF1 VEGFA
15 submucous uterine fibroid 10.6 ALB INS VEGFA
16 perineurioma 10.6 ICAM1 PLG VEGFA
17 phlegmonous dacryocystitis 10.6 ICAM1 KDR VEGFA
18 capillary hemangioma 10.6 ALB MTHFR PLG
19 lichen planus 10.6 ICAM1 SERPINF1 VEGFA
20 aryepiglottic fold cancer 10.6 ALB MTHFR PLG
21 ovarian hyperstimulation syndrome 10.5 ALB KDR VEGFA
22 fuhrmann syndrome 10.5 KDR MTHFR VEGFA
23 hyperostosis, endosteal 10.5 FZD4 LRP5 NDP
24 kidney pelvis papillary carcinoma 10.5 FLT1 KDR VEGFA
25 conventional angiosarcoma 10.5 HBA1 VEGFA
26 coloboma of superior eyelid 10.5 FLT1 KDR VEGFA
27 astigmatism 10.5 FZD4 LRP5 NDP
28 metal metabolism disorder 10.4 INS VEGFA
29 vascular disease 10.4
30 retinitis 10.4
31 fissured tongue 10.4 AKR1B1 ALB INS
32 middle lobe syndrome 10.4 CTGF ICAM1 VEGFA
33 diffuse large b-cell lymphoma 10.4 AKR1B1 INS VEGFA
34 extragonadal germ cell cancer 10.4 HBA1 KDR VEGFA
35 periampullary adenoma 10.4 ICAM1 INS VEGFA
36 vesiculobullous skin disease 10.4 HBA1 KDR VEGFA
37 preeclampsia/eclampsia 1 10.4 FLT1 MTHFR VEGFA
38 factitious disorder 10.4 HBA1 KDR VEGFA
39 hidradenoma 10.4 FLT1 KDR VEGFA
40 posterior foramen magnum meningioma 10.4 HBA1 KDR VEGFA
41 chikungunya 10.4 FLT1 KDR VEGFA
42 retinitis pigmentosa 17 10.4 AKR1B1 ALB CTGF INS
43 colonic l-cell glucagon-like peptide producing tumor 10.3 HBA1 PLG
44 breast fibroadenoma 10.3 INS VEGFA
45 vulvar dystrophy 10.3 HBA1 INS
46 arthrogryposis, ectodermal dysplasia, cleft lip/palate, and developmental delay 10.3 FZD4 KDR NDP TSPAN12 VEGFA
47 nystagmus 5, congenital, x-linked 10.3 FZD4 LRP5 NDP TSPAN12
48 pleural tuberculosis 10.2 ALB FLT1 MTHFR VEGFA
49 salivary gland adenoid cystic carcinoma 10.2 FLT1 HBA1 VEGFA
50 lens disease 10.1 FLT1 KDR OCLN VEGFA

Graphical network of the top 20 diseases related to Retinal Vascular Disease:



Diseases related to Retinal Vascular Disease

Symptoms & Phenotypes for Retinal Vascular Disease

UMLS symptoms related to Retinal Vascular Disease:


chest pain

MGI Mouse Phenotypes related to Retinal Vascular Disease:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.29 TSPAN12 VEGFA CTGF FLT1 FZD4 ICAM1
2 homeostasis/metabolism MP:0005376 10.25 AKR1B1 ALB CTGF FLT1 FZD4 ICAM1
3 growth/size/body region MP:0005378 10.23 AKR1B1 CTGF FLT1 FZD4 ICAM1 INS
4 digestive/alimentary MP:0005381 10.15 ALB CTGF FZD4 ICAM1 INS OCLN
5 endocrine/exocrine gland MP:0005379 10.13 ALB FZD4 ICAM1 INS LRP5 OCLN
6 nervous system MP:0003631 10.07 AIPL1 FLT1 FZD4 ICAM1 INS KDR
7 integument MP:0010771 10.01 CTGF FZD4 ICAM1 INS KDR MTHFR
8 muscle MP:0005369 9.92 FZD4 ICAM1 INS KDR OCLN VEGFA
9 liver/biliary system MP:0005370 9.85 INS ALB KDR LRP5 PLG VEGFA
10 reproductive system MP:0005389 9.81 FLT1 FZD4 INS MTHFR NDP OCLN
11 skeleton MP:0005390 9.65 OCLN SERPINF1 VEGFA MTHFR NDP AKR1B1
12 vision/eye MP:0005391 9.5 AIPL1 AKR1B1 CTGF FLT1 FZD4 ICAM1

Drugs & Therapeutics for Retinal Vascular Disease

Drugs for Retinal Vascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 362)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
2
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1 347396-82-1 459903
3
Glatiramer Acetate Approved, Investigational Phase 4 147245-92-9 3081884
4
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
5
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 124-94-7 31307
6
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
8
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 5460373 44475014
9
Fenofibrate Approved Phase 4,Phase 3 49562-28-9 3339
10
Verteporfin Approved, Investigational Phase 4 129497-78-5
11
Zinc Approved Phase 4,Phase 3,Phase 2,Early Phase 1 7440-66-6 32051 23994
12
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
13
Copper Approved Phase 4 7440-50-8 27099
14
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
15
Trandolapril Approved Phase 4 87679-37-6 5484727
16
Verapamil Approved Phase 4 52-53-9 2520
17
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
18
Travoprost Approved Phase 4 157283-68-6 5282226
19
Dipivefrin Approved Phase 4 52365-63-6 3105
20
Temazepam Approved Phase 4,Phase 3,Phase 2 846-50-4 5391
21
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
23
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
24
Pyridoxal Approved, Nutraceutical Phase 4 66-72-8 1050
25
Pyridoxine Approved, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
26
Glucosamine Approved, Nutraceutical Phase 4,Phase 1,Phase 2 3416-24-8 439213
27 Tocopherol Approved, Nutraceutical Phase 4
28
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
29
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
30
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
31
Choline Approved, Nutraceutical Phase 4 62-49-7 305
32
Lactitol Investigational Phase 4,Phase 1,Phase 2 585-86-4 3871
33 Endothelial Growth Factors Phase 4,Phase 3,Phase 2,Phase 1
34 Mitogens Phase 4,Phase 3,Phase 2,Phase 1
35 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
36 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Adjuvants, Immunologic Phase 4,Phase 1
38 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
39 diuretics Phase 4,Phase 3
40 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Natriuretic Agents Phase 4,Phase 3
42 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 triamcinolone acetonide Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Triamcinolone diacetate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Triamcinolone hexacetonide Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 682)

id Name Status NCT ID Phase Drugs
1 Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial) Unknown status NCT02092532 Phase 4 Rescue Intravitreal Aflibercept Injection
2 Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy Unknown status NCT01857544 Phase 4 Aflibercept
3 Retinal Sensitivity in BRVO After Anti-VEGF Therapy Unknown status NCT02527733 Phase 4 Ranibizumab;Ranibizumab and laser
4 Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation Unknown status NCT00677664 Phase 4 Glatiramer acetate (Copaxone);Mannitol
5 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
6 Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED) Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
7 Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO Unknown status NCT00566761 Phase 4 bevacizumab and triamcinolone
8 Changes in Macular Thickness After Patterns Scan Laser Unknown status NCT00563628 Phase 4
9 PASCAL Laser Versus ETDRS Laser Associated With Intravitreal Ranibizumab (IVR) Versus Only IVR for Proliferative Diabetic Retinopathy Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
10 IntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids Unknown status NCT00744666 Phase 4 Prednisolone 1% topical eye drops
11 Ranibizumab in Diabetic Vitrectomy Unknown status NCT01306981 Phase 4 Ranibizumab;Saline
12 The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease Unknown status NCT01306955 Phase 4 methylorednisolone
13 Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment Unknown status NCT00563043 Phase 4
14 Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy Unknown status NCT01382498 Phase 4 Calcium dobesilate (Doxium);Placebo drug
15 The Prediction of Extent and Risk Profile of Coronary Atherosclerosis and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques Unknown status NCT01773512 Phase 4 Rosuvastatin
16 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
17 Effects of Fenofibrate on Endothelial Progenitor Cells in Diabetes Unknown status NCT01927315 Phase 4 Fenofibrate 145 mg;Placebo
18 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
19 Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study Completed NCT01486238 Phase 4 Macugen® pegaptanib sodium
20 Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy Completed NCT00674323 Phase 4 Verteporfin Photodynamic Therapy;Ranibizumab
21 Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation Completed NCT01871376 Phase 4 Intravitreal aflibercept injection 2.0mg
22 PDT Study for Exudative AMD With PCV Completed NCT00331435 Phase 4
23 Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Completed NCT01950741 Phase 4 aflibercept
24 Visual Outcome in Patients With Symptomatic Macular PCV Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy. Completed NCT01846273 Phase 4 Ranibizumab;Verteporfin PDT;Sham PDT
25 Effect of Antioxidants on Ocular Blood Flow, Endothelial Function, and Cytokine Levels in LPS Induced Inflammatory Model in Humans. Completed NCT00431691 Phase 4 vitamin and mineral supplement;Escherichia coli Endotoxin (LPS);100% O2;nitroglycerin
26 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Completed NCT00682240 Phase 4
27 Ranibizumab in Patients With Branch Retinal Vein Occlusion Completed NCT01027481 Phase 4 Lucentis
28 Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Completed NCT01710839 Phase 4 0.5mg Ranibizumab
29 A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT) Completed NCT00235014 Phase 4 trandolapril;trandolapril/verapamil;placebo;verapamil
30 Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion Completed NCT00406107 Phase 4 pegaptanib sodium (Macugen)
31 NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions Completed NCT01870427 Phase 4 Aflibercept (2.0 mg)
32 Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion Completed NCT01448018 Phase 4 ranibizumab
33 Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion Completed NCT01085734 Phase 4 Avastin;Osurdex;Avastin
34 Influence of Prostaglandins on Ocular Blood Flow in Glaucoma Patients Completed NCT00308945 Phase 4 travoprost 0.004% (drug);latanoprost 0.005% (drug)
35 Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion Completed NCT01427751 Phase 4 dexamethasone intravitreal implant
36 A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion Completed NCT01903720 Phase 4 dexamethasone implant
37 A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion Completed NCT01277302 Phase 4 Ranibizumab
38 Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO Completed NCT01580020 Phase 4 Dexamethasone
39 Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy. Completed NCT00802269 Phase 4
40 Dexamethasone-implant for the Treatment of RVO Completed NCT01767545 Phase 4 Dexamethasone implant;Bevacizumab
41 Effect of the Adjunctive IVB Before PRP Completed NCT01504724 Phase 4 bevacizumab
42 Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients. Completed NCT01997489 Phase 4 Enzyme replacement
43 Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema. Completed NCT02140411 Phase 4 Ranibizumab Intravitreal injections
44 Unilateral Bevacizumab for Bilateral Diabetic Macular Edema Completed NCT00496405 Phase 4 bevacizumab
45 Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation Completed NCT01223612 Phase 4 Ranibizumab
46 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Completed NCT03046693 Phase 4 Group A Citicoline 1000 mg oral tablet;Group B placebo oral tablet
47 Neural Conduction Along the Visual Pathways After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases Completed NCT00404729 Phase 4 Cytidine-5’-diphosphocholine (Citicoline)
48 Vascular Endothelial Growth Factor in Stage V ROP Completed NCT00500396 Phase 4
49 Topical Application of Latanoprost in Diabetic Retinopathy Completed NCT01225653 Phase 4 Latanoprost
50 Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab

Search NIH Clinical Center for Retinal Vascular Disease

Genetic Tests for Retinal Vascular Disease

Anatomical Context for Retinal Vascular Disease

MalaCards organs/tissues related to Retinal Vascular Disease:

39
Eye, Endothelial, Retina, Kidney, Testes, Bone, Brain

Publications for Retinal Vascular Disease

Articles related to Retinal Vascular Disease:

(show top 50) (show all 63)
id Title Authors Year
1
Microscope-Integrated Optical Coherence Tomography Angiography in the Operating Room in Young Children With Retinal Vascular Disease. ( 28384676 )
2017
2
Do photoreceptor cells cause the development of retinal vascular disease? ( 28438678 )
2017
3
Cell Therapy Applications for Retinal Vascular Diseases: Diabetic Retinopathy and Retinal Vein Occlusion. ( 27116667 )
2016
4
Adult lead exposure increases blood-retinal permeability: A risk factor for retinal vascular disease. ( 27663850 )
2016
5
Nanoengineering of therapeutics for retinal vascular disease. ( 26022642 )
2015
6
Systemic atheromatosis influence on retinal vascular disease. ( 25729610 )
2014
7
[Cytokine determination from vitreous samples in retinal vascular diseases]. ( 23224211 )
2013
8
Regional morphology and pathophysiology of retinal vascular disease. ( 23892140 )
2013
9
Changes in the foveal microstructure after intravitreal bevacizumab application in patients with retinal vascular disease. ( 23355773 )
2013
10
Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease? ( 22250209 )
2012
11
The role of glia in retinal vascular disease. ( 22519424 )
2012
12
Retinal vascular disease and the pathogenesis of facioscapulohumeral muscular dystrophy. A signalling message from Wnt? ( 21377364 )
2011
13
The multifactorial nature of retinal vascular disease. ( 20714177 )
2010
14
Molecular targets for retinal vascular diseases. ( 17133346 )
2007
15
[Aging and retinal vascular diseases]. ( 17402563 )
2007
16
Newly recognized serous macular detachment in retinal vascular disease. ( 16770254 )
2006
17
Retinal vascular disease in hypertension. Risk factor modification optimizes vision outcomes. ( 16001767 )
2005
18
Methylenetetrahydrofolate reductase gene polymorphism, hyperhomocysteinemia and occlusive retinal vascular disease in type 2 diabetic and non-diabetic subjects. ( 12356186 )
2002
19
Plasma total homocysteine and retinal vascular disease. ( 11040905 )
2000
20
Association of antiphospholipid antibodies with retinal vascular disease in systemic lupus erythematosus. ( 10342390 )
1999
21
Ambulatory blood pressure monitoring in cerebrovascular and retinal vascular disease. ( 17895021 )
1997
22
Ambulatory blood pressure monitoring in cerebrovascular and retinal vascular disease. ( 17895027 )
1997
23
Antiphospholipid antibodies and retinal vascular disease. ( 8869905 )
1996
24
On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy. ( 23573590 )
1995
25
On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy. ( 7739630 )
1995
26
Retinal vascular disease in ulcerative colitis. ( 8085600 )
1994
27
Arnall Patz Medal for Excellence in Retinal Vascular Disease. Matthew D. Davis, MD. ( 1439249 )
1992
28
Cerebral ischemic events associated with endocarditis, retinal vascular disease, and lupus anticoagulant. ( 1900660 )
1991
29
Antiphospholipid antibodies associated with retinal vascular disease. ( 2133045 )
1990
30
Semiconductor diode laser photocoagulation in retinal vascular disease. ( 2255529 )
1990
31
The patency of the retinal vasculature to erythrocytes in retinal vascular disease. ( 2318585 )
1990
32
Crohn's disease and retinal vascular disease. ( 2220968 )
1990
33
Initial clinical experience using a diode laser in the treatment of retinal vascular disease. ( 2630328 )
1989
34
Occlusive retinal vascular disease in two patients. ( 2788911 )
1989
35
The tunable dye laser in the management of retinal vascular disease. ( 3229908 )
1988
36
Antiphospholipid antibodies associated with retinal vascular disease. ( 3124231 )
1987
37
The eyes of Woodrow Wilson. Retinal vascular disease and George de Schweinitz. ( 3887267 )
1985
38
Occlusive retinal vascular disease in systemic lupus erythematosus. ( 6084063 )
1984
39
Treatment of retinal vascular disease using photocoagulation and cryotherapy. ( 6676223 )
1983
40
Digital subtraction angiography in the diagnosis of retinal vascular disease. ( 6195923 )
1983
41
Photocoagulation in retinal vascular disease. ( 281780 )
1977
42
Retinal vascular disease: introduction and phenomenology. ( 888253 )
1977
43
Selected molecular weight dextrans for in vivo permeability studies of rat retinal vascular disease. ( 872904 )
1977
44
Symposium on retinal vascular disease. Conclusion. ( 1070875 )
1976
45
Occlusive retinal vascular disease and deafness. ( 949074 )
1976
46
Clinical understanding in the management of retinal vascular disease. ( 1070871 )
1976
47
Retinal vascular disease. ( 4415614 )
1974
48
Evolution of hypertensive retinal vascular disease: correlation between clinical and postmortem observations. ( 4748590 )
1973
49
Photocoagulation of retinal vascular disease. ( 4507180 )
1972
50
Platelet aggregation studies in ischaemic retinal vascular disease. ( 5291525 )
1971

Variations for Retinal Vascular Disease

Expression for Retinal Vascular Disease

Search GEO for disease gene expression data for Retinal Vascular Disease.

Pathways for Retinal Vascular Disease

GO Terms for Retinal Vascular Disease

Cellular components related to Retinal Vascular Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 ALB CTGF FLT1 HBA1 INS KDR
2 extracellular space GO:0005615 9.36 AKR1B1 ALB CTGF FLT1 HBA1 ICAM1
3 platelet alpha granule lumen GO:0031093 9.33 ALB PLG VEGFA

Biological processes related to Retinal Vascular Disease according to GeneCards Suite gene sharing:

(show all 22)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.98 AIPL1 AKR1B1 ALB KDR VEGFA
2 positive regulation of cell proliferation GO:0008284 9.85 CTGF FLT1 INS KDR LRP5 VEGFA
3 positive regulation of cell migration GO:0030335 9.81 FLT1 INS KDR VEGFA
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.75 ICAM1 INS VEGFA
5 positive regulation of MAPK cascade GO:0043410 9.74 FLT1 INS KDR
6 canonical Wnt signaling pathway GO:0060070 9.72 FZD4 LRP5 NDP
7 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.71 FLT1 KDR VEGFA
8 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.7 FLT1 INS KDR
9 vasculogenesis GO:0001570 9.67 FZD4 KDR VEGFA
10 angiogenesis GO:0001525 9.65 CTGF FLT1 KDR TSPAN12 VEGFA
11 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.61 FLT1 VEGFA
12 cell migration involved in sprouting angiogenesis GO:0002042 9.6 KDR VEGFA
13 negative regulation of cell-substrate adhesion GO:0010812 9.59 FZD4 PLG
14 positive regulation of positive chemotaxis GO:0050927 9.56 KDR VEGFA
15 response to amino acid GO:0043200 9.5 CTGF ICAM1 MTHFR
16 vascular endothelial growth factor signaling pathway GO:0038084 9.48 FLT1 KDR
17 regulation of cGMP metabolic process GO:0030823 9.46 AIPL1 VEGFA
18 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.43 KDR VEGFA
19 retinal blood vessel morphogenesis GO:0061304 9.4 FZD4 LRP5
20 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.33 FLT1 KDR VEGFA
21 retina vasculature morphogenesis in camera-type eye GO:0061299 9.13 FZD4 LRP5 NDP
22 extracellular matrix-cell signaling GO:0035426 8.8 FZD4 LRP5 NDP

Molecular functions related to Retinal Vascular Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 AIPL1 ALB CTGF FLT1 FZD4 HBA1
2 vascular endothelial growth factor-activated receptor activity GO:0005021 9.16 FLT1 KDR
3 Wnt-activated receptor activity GO:0042813 8.8 FZD4 LRP5 TSPAN12

Sources for Retinal Vascular Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....